180 related articles for article (PubMed ID: 38226713)
1. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Lebwohl M; Warren RB; Sofen H; Imafuku S; Paul C; Szepietowski JC; Spelman L; Passeron T; Vritzali E; Napoli A; Kisa RM; Buck A; Banerjee S; Thaçi D; Blauvelt A
Br J Dermatol; 2024 Apr; 190(5):668-679. PubMed ID: 38226713
[TBL] [Abstract][Full Text] [Related]
2. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
Armstrong AW; Park SH; Patel V; Hogan M; Wang WJ; Davidson D; Chirikov V
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2589-2603. PubMed ID: 37525000
[TBL] [Abstract][Full Text] [Related]
3. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S; Okubo Y; Tada Y; Ohtsuki M; Colston E; Napoli A; Shao Y; Banerjee S; Morita A
J Dermatol; 2024 Mar; 51(3):365-379. PubMed ID: 38268101
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
[TBL] [Abstract][Full Text] [Related]
5. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A
J Am Acad Dermatol; 2023 Jan; 88(1):29-39. PubMed ID: 35820547
[TBL] [Abstract][Full Text] [Related]
6. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Strober B; Blauvelt A; Warren RB; Papp KA; Armstrong AW; Gordon KB; Morita A; Alexis AF; Lebwohl M; Foley P; Kisa RM; Colston E; Wang T; Banerjee S; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Mar; ():. PubMed ID: 38451052
[TBL] [Abstract][Full Text] [Related]
7. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
Immunotherapy; 2023 Aug; 15(11):787-797. PubMed ID: 37150956
[TBL] [Abstract][Full Text] [Related]
8. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
J Am Acad Dermatol; 2023 Jan; 88(1):40-51. PubMed ID: 36115523
[TBL] [Abstract][Full Text] [Related]
9. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A
Immunotherapy; 2023 Aug; 15(12):963-973. PubMed ID: 37150952
[TBL] [Abstract][Full Text] [Related]
10. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
Truong TM; Pathak GN; Singal A; Taranto V; Rao BK
Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177
[TBL] [Abstract][Full Text] [Related]
11. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Blauvelt A; Rich P; Sofen H; Strober B; Merola JF; Lebwohl M; Morita A; Szepietowski JC; Lambert J; Hippeli L; Colston E; Balagula E; Banerjee S; Thaçi D
J Am Acad Dermatol; 2024 Apr; 90(4):775-782. PubMed ID: 38122848
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Liu J; Liu W; Lin F; Shi N
Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
[TBL] [Abstract][Full Text] [Related]
13. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Gooderham MJ; Hong HC; Litvinov IV
Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
15. Deucravacitinib for the Treatment of Psoriatic Disease.
Lé AM; Puig L; Torres T
Am J Clin Dermatol; 2022 Nov; 23(6):813-822. PubMed ID: 35960487
[TBL] [Abstract][Full Text] [Related]
16. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
18. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
[TBL] [Abstract][Full Text] [Related]
19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
20. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
